Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases

International Journal of Clinical and Experimental Medicine

Volumn 3, Issue 3, 2010, Pages 233-244

  Zhang, Jianliang ^a   Patel, Jawaharlal M ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chemokine; COPD; Endothelium; Fractalkine; Inflammation; Pulmonary; Vasculature

Indexed keywords

ADAM PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE;

AIRWAY REMODELING; CELL INFILTRATION; CELL STIMULATION; CHEMOTAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DENDRITIC CELL; HUMAN; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LUNG BLOOD VESSEL; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MEDIATOR RELEASE; MONOCYTE; MONONUCLEAR CELL; NATURAL KILLER CELL; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

EID: 77956646923     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Agostini C, Trentin L and Adami F. Chronic obstructive pulmonary disease (COPD): new insights on the events leading to pulmonary inflammation. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 3-7.
2. Chung KF and Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008; 31: 1334-1356.
3. Cosio MG and Majo J. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest 2002; 121: 160S-165S.
4. Joppa P, Petrasova D, Stancak B and Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006; 130: 326-333.
5. Kardos P and Keenan J. Tackling COPD: a multicomponent disease driven by inflammation. MedGenMed 2006; 8: 54.
6. Rahman I and Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006; 28: 219-242.
7. Rajendrasozhan S, Yang SR, Edirisinghe I, Yao H, Adenuga D and Rahman I. Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid Redox Signal 2008; 10: 799-811.
8. Roth M. Pathogenesis of COPD. Part III. Inflammation in COPD. Int J Tuberc Lung Dis 2008; 12: 375-380.
9. Yawn BP and Kaplan A. Co-morbidities in people with COPD: a result of multiple diseases, or multiple manifestations of smoking and reactive inflammation? Prim Care Respir J 2008; 17: 199-205.
10. Ziesche R, Petkov V, Mosgoller W and Block LH. Regulation of human endothelial nitric oxide synthase by hypoxia and inflammation in human pulmonary arteries--implications for the therapy of pulmonary hypertension in COPD patients. Acta Anaesthesiol Scand Suppl 1996; 109: 97-98.
11. Herget J, Palecek F, Preclik P, Cermakova M, Vizek M and Petrovicka M. Pulmonary hypertension induced by repeated pulmonary inflammation in the rat. J Appl Physiol 1981; 51: 755-761.
12. Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S and Eddahibi S. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 2009; 10: 6.
13. Song Y, Coleman L, Shi J, Beppu H, Sato K, Walsh K, Loscalzo J and Zhang YY. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2- mutant mice. Am J Physiol Heart Circ Physiol 2008; 295: H677-690.
14. Tuder RM, Groves B, Badesch DB and Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275-285.
15. Voelkel NF and Tuder R. Interleukin-1 receptor antagonist inhibits pulmonary hypertension induced by inflammation. Ann N Y Acad Sci 1994; 725: 104-109.
16. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ and Stenmark KR. Circulating mononuclear cells with a dual, macrophagefibroblast phenotype contribute robustly to hypoxia-induced pulmonary adventitial remodeling. Chest 2005; 128: 583S-584S.
17. Stenmark KR, Davie NJ, Reeves JT and Frid MG. Hypoxia, leukocytes, and the pulmonary circulation. J Appl Physiol 2005; 98: 715-721.
18. Ancuta P, Wang J and Gabuzda D. CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase- 9 upon interaction with CX3CL1- expressing endothelial cells. J Leukoc Biol 2006; 80: 1156-1164.
19. Imaizumi T, Matsumiya T, Fujimoto K, Okamoto K, Cui X, Ohtaki U, Hidemi, Yoshida and Satoh K. Interferon-gamma stimulates the expression of CX3CL1/fractalkine in cultured human endothelial cells. Tohoku J Exp Med 2000; 192: 127-139.
20. Harrison JK, Jiang Y, Wees EA, Salafranca MN, Liang HX, Feng L and Belardinelli L. Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. J Leukoc Biol 1999; 66: 937-944.
21. Manes TD and Pober JS. Antigen presentation by human microvascular endothelial cells triggers ICAM-1-dependent transendothelial protrusion by, and fractalkine-dependent transendothelial migration of, effector memory CD4+ T cells. J Immunol 2008; 180: 8386-8392.
22. Moatti D, Vele O and Nemerson Y. Induction of fractalkine by endothelial cells under shear stress. Blood Coagul Fibrinolysis 2004; 15: 197.
23. Schulz C, Schafer A, Stolla M, Kerstan S, Lorenz M, von Bruhl ML, Schiemann M, Bauersachs J, Gloe T, Busch DH, Gawaz M and Massberg S. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation 2007; 116: 764-773.
24. Cambien B, Pomeranz M, Schmid-Antomarchi H, Millet MA, Breittmayer V, Rossi B and Schmid-Alliana A. Signal transduction pathways involved in soluble fractalkine-induced monocytic cell adhesion. Blood 2001; 97: 2031-2037.
25. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T and Patel DD. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998; 188: 1413-1419.
26. Goda S, Imai T, Yoshie O, Yoneda O, Inoue H, Nagano Y, Okazaki T, Imai H, Bloom ET, Domae N and Umehara H. CX3C-chemokine, fractalkine- enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol 2000; 164: 4313-4320.
27. Green SR, Han KH, Chen Y, Almazan F, Charo IF, Miller YI and Quehenberger O. The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 MAPK. J Immunol 2006; 176: 7412-7420.
28. Guo J, Chen T, Wang B, Zhang M, An H, Guo Z, Yu Y, Qin Z and Cao X. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol Lett 2003; 89: 1-7.
29. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ and Yoshie O. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91: 521-530.
30. Yoshikawa M, Nakajima T, Matsumoto K, Okada N, Tsukidate T, Iida M, Otori N, Haruna S, Moriyama H, Imai T and Saito H. TNF-alpha and IL-4 regulate expression of fractalkine (CX3CL1) as a membrane-anchored proadhesive protein and soluble chemotactic peptide on human fibroblasts. FEBS Lett 2004; 561: 105-110.
31. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ and Raines EW. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001; 276: 37993-38001.
32. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen KJ, Rose-John S and Ludwig A. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003; 102: 1186-1195.
33. Seals DF and Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003; 17: 7-30.
34. Le Gall SM, Bobe P, Reiss K, Horiuchi K, Niu XD, Lundell D, Gibb DR, Conrad D, Saftig P and Blobel CP. ADAMs 10 and 17 Represent Differentially Regulated Components of a General Shedding Machinery for Membrane Proteins such as TGF{alpha}, L-Selectin and TNF{alpha}. Mol Biol Cell 2009; 20:1785-1794.
35. Blobel CP. Functional and biochemical characterization of ADAMs and their predicted role in protein ectodomain shedding. Inflamm Res 2002; 51: 83-84.
36. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ and Cerretti DP. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-733.
37. Moss ML, Jin SL, Becherer JD, Bickett DM, Burkhart W, Chen WJ, Hassler D, Leesnitzer MT, McGeehan G, Milla M, Moyer M, Rocque W, Seaton T, Schoenen F, Warner J and Willard D. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J Neuroimmunol 1997; 72: 127-129.
38. Schulte A, Schulz B, Andrzejewski MG, Hundhausen C, Mletzko S, Achilles J, Reiss K, Paliga K, Weber C, John SR and Ludwig A. Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha- and gammasecretases. Biochem Biophys Res Commun 2007; 358: 233-240.
39. McComb JG, Ranganathan M, Liu XH, Pilewski JM, Ray P, Watkins SC, Choi AM and Lee JS. CX3CL1 up-regulation is associated with recruitment of CX3CR1+ mononuclear phagocytes and T lymphocytes in the lungs during cigarette smoke-induced emphysema. Am J Pathol 2008; 173: 949-961.
40. Zhang X, Wei H, Wang H and Tian Z. Involvement of interaction between Fractalkine and CX3CR1 in cytotoxicity of natural killer cells against tumor cells. Oncol Rep 2006; 15: 485-488.
41. Raoul W, Feumi C, Keller N, Lavalette S, Houssier M, Behar-Cohen F, Combadiere C and Sennlaub F. Lipid-bloated subretinal microglial cells are at the origin of drusen appearance in CX3CR1-deficient mice. Ophthalmic Res 2008; 40: 115-119.
42. Zanchi C, Zoja C, Morigi M, Valsecchi F, Liu XY, Rottoli D, Locatelli M, Buelli S, Pezzotta A, Mapelli P, Geelen J, Remuzzi G and Hawiger J. Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin. J Immunol 2008; 181: 1460-1469.
43. Truman LA, Ford CA, Pasikowska M, Pound JD, Wilkinson SJ, Dumitriu IE, Melville L, Melrose LA, Ogden CA, Nibbs R, Graham G, Combadiere C and Gregory CD. CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood 2008; 112: 5026-5036.
44. Gevrey JC, Isaac BM and Cox D. Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (Fractalkine). J Immunol 2005; 175: 3737-3745.
45. Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM and Greaves DR. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 2003; 108: 2498-2504.
46. Yang Q, Underwood MJ, Hsin MK, Liu XC and He GW. Dysfunction of pulmonary vascular endothelium in chronic obstructive pulmonary disease: basic considerations for future drug development. Curr Drug Metab 2008; 9: 661-667.
47. Peinado VI, Barbera JA, Abate P, Ramirez J, Roca J, Santos S and Rodriguez-Roisin R. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1605-1611.
48. Brantly ML, Paul LD, Miller BH, Falk RT, Wu M and Crystal RG. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis 1988; 138: 327-336.
49. Dinh-Xuan AT, Higenbottam TW, Clelland CA, Pepke-Zaba J, Cremona G, Butt AY, Large SR, Wells FC and Wallwork J. Impairment of endothelium- dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991; 324: 1539-1547.
50. Michiels C, Arnould T and Remacle J. Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions. Biochim Biophys Acta 2000; 1497: 1-10.
51. Di Stefano A, Caramori G, Ricciardolo FL, Capelli A, Adcock IM and Donner CF. Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview. Clin Exp Allergy 2004; 34: 1156-1167.
52. Ning W, Li CJ, Kaminski N, Feghali-Bostwick CA, Alber SM, Di YP, Otterbein SL, Song R, Hayashi S, Zhou Z, Pinsky DJ, Watkins SC, Pilewski JM, Sciurba FC, Peters DG, Hogg JC and Choi AM. Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 2004; 101: 14895-14900.
53. Le Quement C, Guenon I, Gillon JY, Valenca S, Cayron-Elizondo V, Lagente V and Boichot E. The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke. Br J Pharmacol 2008; 154: 1206-1215.
54. Stenmark KR, Fagan KA and Frid MG. Hypoxiainduced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006; 99: 675-691.
55. Tuder RM, Yun JH, Bhunia A and Fijalkowska I. Hypoxia and chronic lung disease. J Mol Med 2007; 85: 1317-1324.
56. Preston IR. Clinical perspective of hypoxiamediated pulmonary hypertension. Antioxid Redox Signal 2007; 9: 711-721.
57. Raguso CA, Guinot SL, Janssens JP, Kayser B and Pichard C. Chronic hypoxia: common traits between chronic obstructive pulmonary disease and altitude. Curr Opin Clin Nutr Metab Care 2004; 7: 411-417.
58. Pierson DJ. Pathophysiology and clinical effects of chronic hypoxia. Respir Care 2000; 45: 39-51; discussion 51-33.
59. Perros F, Dorfmuller P, Souza R, Durand-Gasselin I, Godot V, Capel F, Adnot S, Eddahibi S, Mazmanian M, Fadel E, Herve P, Simonneau G, Emilie D and Humbert M. Fractalkineinduced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 2007; 29: 937-943.
60. Stievano L, Piovan E and Amadori A. C and CX3C chemokines: cell sources and physiopathological implications. Crit Rev Immunol 2004; 24: 205-228.
61. Balabanian K, Foussat A, Dorfmuller P, Durand-Gasselin I, Capel F, Bouchet-Delbos L, Portier A, Marfaing-Koka A, Krzysiek R, Rimaniol AC, Simonneau G, Emilie D and Humbert M. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 1419-1425.
62. Ryu J, Lee CW, Hong KH, Shin JA, Lim SH, Park CS, Shim J, Nam KB, Choi KJ, Kim YH and Han KH. Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia. Cardiovasc Res 2008; 78: 333-340.
63. Hasegawa M, Sato S, Echigo T, Hamaguchi Y, Yasui M and Takehara K. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis 2005; 64: 21-28.
64. Marasini B, Cossutta R, Selmi C, Pozzi MR, Gardinali M, Massarotti M, Erario M, Battaglioli L and Biondi ML. Polymorphism of the fractalkine receptor CX3CR1 and systemic sclerosis -associated pulmonary arterial hypertension. Clin Dev Immunol 2005; 12: 275-279.
65. Dragomir E, Manduteanu I, Calin M, Gan AM, Stan D, Koenen RR, Weber C and Simionescu M. High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein- 1 in human smooth muscle cells. Thromb Haemost 2008; 100: 1155-1165.
66. Fujimoto K, Imaizumi T, Yoshida H, Takanashi S, Okumura K and Satoh K. Interferon-gamma stimulates fractalkine expression in human bronchial epithelial cells and regulates mononuclear cell adherence. Am J Respir Cell Mol Biol 2001; 25: 233-238.
67. Hatakeyama M, Imaizumi T, Tamo W, Yamashita K, Yoshida H, Fukuda I and Satoh K. Heparin inhibits IFN-gamma-induced fractalkine/ CX3CL1 expression in human endothelial cells. Inflammation 2004; 28: 7-13.
68. Manduteanu I, Dragomir E, Calin M, Pirvulescu M, Gan AM, Stan D and Simionescu M. Resistin up-regulates fractalkine expression in human endothelial cells: lack of additive effect with TNF-alpha. Biochem Biophys Res Commun 2009; 381: 96-101.
69. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol 2008; 28: 1950-1959.
70. Weber C, Schober A and Zernecke A. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 1997-2008.
71. Liu P, Patil S, Rojas M, Fong AM, Smyth SS and Patel DD. CX3CR1 deficiency confers protection from intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 2006; 26: 2056-2062.
72. Csiszar A, Podlutsky A, Wolin MS, Losonczy G, Pacher P and Ungvari Z. Oxidative stress and accelerated vascular aging: implications for cigarette smoking. Front Biosci 2009; 14: 3128-3144.
73. Rudolph TK, Rudolph V and Baldus S. Contribution of myeloperoxidase to smoking-dependent vascular inflammation. Proc Am Thorac Soc 2008; 5: 820-823.
74. Yong T, Zheng MQ and Linthicum DS. Nicotine induces leukocyte rolling and adhesion in the cerebral microcirculation of the mouse. J Neuroimmunol 1997; 80: 158-164.
75. Shen Y, Rattan V, Sultana C and Kalra VK. Cigarette smoke condensate-induced adhesion molecule expression and transendothelial migration of monocytes. Am J Physiol 1996; 270: H1624-1633.
76. Lehr HA, Frei B and Arfors KE. Vitamin C prevents cigarette smoke-induced leukocyte aggregation and adhesion to endothelium in vivo. Proc Natl Acad Sci USA 1994; 91: 7688-7692.
77. Kalra VK, Ying Y, Deemer K, Natarajan R, Nadler JL and Coates TD. Mechanism of cigarette smoke condensate induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 1994; 160: 154-162.
78. Rao SP, Sikora L, Hosseinkhani MR, Pinkerton KE and Sriramarao P. Exposure to environmental tobacco smoke induces angiogenesis and leukocyte trafficking in lung microvessels. Exp Lung Res 2009; 35: 119-135.
79. Auffray C, Fogg DK, Narni-Mancinelli E, Senechal B, Trouillet C, Saederup N, Leemput J, Bigot K, Campisi L, Abitbol M, Molina T, Charo I, Hume DA, Cumano A, Lauvau G and Geissmann F. CX3CR1+ CD115+ CD135+ common macrophage/ DC precursors and the role of CX3CR1 in their response to inflammation. J Exp Med 2009; 206: 595-606.
80. Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, Merval R, Proudfoot A, Tedgui A and Mallat Z. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008; 117: 1649-1657.
81. Brozyna S, Ahern J, Hodge G, Nairn J, Holmes M, Reynolds PN and Hodge S. Chemotactic mediators of Th1 T-cell trafficking in smokers and COPD patients. Copd 2009; 6: 4-16.
82. Donnelly LE and Barnes PJ. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 2006; 27: 546-553.
83. Panina-Bordignon P and D'Ambrosio D. Chemokines and their receptors in asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2003; 9: 104-110.
84. Sabroe I, Lloyd CM, Whyte MK, Dower SK, Williams TJ and Pease JE. Chemokines, innate and adaptive immunity, and respiratory disease. Eur Respir J 2002; 19: 350-355.
85. Nicolls MR and Voelkel NF. Hypoxia and the lung: beyond hypoxic vasoconstriction. Antioxid Redox Signal 2007; 9: 741-743.
86. Voelkel NF and Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995; 8: 2129-2138.
87. Schlichting CL, Schareck WD and Weis M. Renal ischemia-reperfusion injury: new implications of dendritic cell-endothelial cell interactions. Transplant Proc 2006; 38: 670-673.
88. Kokura S, Wolf RE, Yoshikawa T, Ichikawa H, Granger DN and Aw TY. Endothelial cells exposed to anoxia/reoxygenation are hyperadhesive to T-lymphocytes: kinetics and molecular mechanisms. Microcirculation 2000; 7: 13-23.
89. Krishnaswamy G, Kelley J, Yerra L, Smith JK and Chi DS. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J Interferon Cytokine Res 1999; 19: 91-104.
90. Maurus CF, Schneider MK, Schmidt D, Zund G and Seebach JD. Activation of human microvascular endothelial cells with TNF-alpha and hypoxia/ reoxygenation enhances NK-cell adhesion, but not NK-Cytotoxicity. Transplantation 2006; 81: 1204-1211.
91. Humbert M. Update in pulmonary arterial hypertension 2007. Am J Respir Crit Care Med 2008; 177: 574-579.
92. Perros F, Dorfmuller P, Souza R, Durand-Gasselin I, Mussot S, Mazmanian M, Herve P, Emilie D, Simonneau G and Humbert M. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J 2007; 29: 462-468.
93. Sanchez O, Marcos E, Perros F, Fadel E, Tu L, Humbert M, Dartevelle P, Simonneau G, Adnot S and Eddahibi S. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2007; 176: 1041-1047.
94. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O and Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 34-40.
95. Bosco MC, Puppo M, Blengio F, Fraone T, Cappello P, Giovarelli M and Varesio L. Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration. Immunobiology 2008; 213: 733-749.
96. Ancuta P, Rao R, Moses A, Mehle A, Shaw SK, Luscinskas FW and Gabuzda D. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003; 197: 1701-1707.
97. Dichmann S, Herouy Y, Purlis D, Rheinen H, Gebicke-Harter P and Norgauer J. Fractalkine induces chemotaxis and actin polymerization in human dendritic cells. Inflamm Res 2001; 50: 529-533.
98. Nevo I, Sagi-Assif O, Meshel T, Ben-Baruch A, Johrer K, Greil R, Trejo LE, Kharenko O, Feinmesser M, Yron I and Witz IP. The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. Cancer Lett 2009; 273: 127-139.
99. Popovic M, Laumonnier Y, Burysek L, Syrovets T and Simmet T. Thrombin-induced expression of endothelial CX3CL1 potentiates monocyte CCL2 production and transendothelial migration. J Leukoc Biol 2008; 84: 215-223.
100. Maeno T, Houghton AM, Quintero PA, Grumelli S, Owen CA and Shapiro SD. CD8+ T Cells are required for inflammation and destruction in cigarette smoke-induced emphysema in mice. J Immunol 2007; 178: 8090-8096.
101. Lemjabbar H, Li D, Gallup M, Sidhu S, Drori E and Basbaum C. Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin. J Biol Chem 2003; 278: 26202-26207.
102. Basbaum C, Li D, Gensch E, Gallup M and Lemjabbar H. Mechanisms by which gram-positive bacteria and tobacco smoke stimulate mucin induction through the epidermal growth factor receptor (EGFR). Novartis Found Symp 2002; 248: 171-176.
103. Fraticelli P, Sironi M, Bianchi G, D'Ambrosio D, Albanesi C, Stoppacciaro A, Chieppa M, Allavena P, Ruco L, Girolomoni G, Sinigaglia F, Vecchi A and Mantovani A. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001; 107: 1173-1181.
104. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, Roedersheimer MT, van Rooijen N and Stenmark KR. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol 2006; 168: 659-669.
105. Karakurum M, Shreeniwas R, Chen J, Pinsky D, Yan SD, Anderson M, Sunouchi K, Major J, Hamilton T, Kuwabara K and et al. Hypoxic induction of interleukin-8 gene expression in human endothelial cells. J Clin Invest 1994; 93: 1564-1570.
106. Buras JA and Reenstra WR. Endothelialneutrophil interactions during ischemia and reperfusion injury: basic mechanisms of hyperbaric oxygen. Neurol Res 2007; 29: 127-131.
107. Matsumiya T, Imaizumi T, Fujimoto K, Cui X, Shibata T, Tamo W, Kumagai M, Tanji K, Yoshida H, Kimura H and Satoh K. Soluble interleukin- 6 receptor alpha inhibits the cytokine- Induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture. Exp Cell Res 2001; 269: 35-41.
108. Lucas AD, Chadwick N, Warren BF, Jewell DP, Gordon S, Powrie F and Greaves DR. The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am J Pathol 2001; 158: 855-866.
109. Ollivier V, Faure S, Tarantino N, Chollet-Martin S, Deterre P, Combadiere C and de Prost D. Fractalkine/CX3CL1 production by human aortic smooth muscle cells impairs monocyte procoagulant and inflammatory responses. Cytokine 2003; 21: 303-311.
110. Bursill CA, Channon KM and Greaves DR. The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curr Opin Lipidol 2004; 15: 145-149.
111. Chandrasekar B, Mummidi S, Perla RP, Bysani S, Dulin NO, Liu F and Melby PC. Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J 2003; 373: 547-558.
112. Chen YM, Tu CJ, Hung KY, Wu KD, Tsai TJ and Hsieh BS. Inhibition by pentoxifylline of TNFalpha- stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-kappa B down-regulation. Br J Pharmacol 2003; 138: 950-958.
113. Ludwig A, Berkhout T, Moores K, Groot P and Chapman G. Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol 2002; 168: 604-612.
114. Sukkar MB, Issa R, Xie S, Oltmanns U, Newton R and Chung KF. Fractalkine/CX3CL1 production by human airway smooth muscle cells: induction by IFN-gamma and TNF-alpha and regulation by TGF-beta and corticosteroids. Am J Physiol Lung Cell Mol Physiol 2004; 287: L1230-1240.
115. Fahy OL, Coates NJ and McColl SR. Inhibition of cytokine-induced fractalkine production by bacterial invasion of human-dermal fibroblasts. Lab Invest 2003; 83: 721-730.
116. Klosowska K, Volin MV, Huynh N, Chong KK, Halloran MM and Woods JM. Fractalkine functions as a chemoattractant for osteoarthritis synovial fibroblasts and stimulates phosphorylation of mitogen-activated protein kinases and Akt. Clin Exp Immunol 2009; 156: 312-319.
117. Sawai H, Park YW, He X, Goronzy JJ and Weyand CM. Fractalkine mediates T cell-dependent proliferation of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum 2007; 56: 3215-3225.
118. Apostolakis S, Krambovitis E, Vlata Z, Kochiadakis GE, Baritaki S and Spandidos DA. CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of preinflammatory stimuli and renin-angiotensin system modulators. Thromb Res 2007; 121: 387-395.
119. Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E, Lira SA, Weissman IL, Weber C and Jung S. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2009; 113: 963-972.
120. Foussat A, Coulomb-L'Hermine A, Gosling J, Krzysiek R, Durand-Gasselin I, Schall T, Balian A, Richard Y, Galanaud P and Emilie D. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol 2000; 30: 87-97.
121. Kobayashi T, Okamoto S, Iwakami Y, Nakazawa A, Hisamatsu T, Chinen H, Kamada N, Imai T, Goto H and Hibi T. Exclusive increase of CX3CR1+CD28-CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes. Inflamm Bowel Dis 2007; 13: 837-846.
122. Muehlhoefer A, Saubermann LJ, Gu X, Luedtke-Heckenkamp K, Xavier R, Blumberg RS, Podolsky DK, MacDermott RP and Reinecker HC. Fractalkine is an epithelial and endothelial cellderived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol 2000; 164: 3368-3376.
123. Nishimura M, Umehara H, Nakayama T, Yoneda O, Hieshima K, Kakizaki M, Dohmae N, Yoshie O and Imai T. Dual functions of fractalkine/ CX3C ligand 1 in trafficking of perforin+/ granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002; 168: 6173-6180.
124. del Rio ML, Rodriguez-Barbosa JI, Bolter J, Ballmaier M, Dittrich-Breiholz O, Kracht M, Jung S and Forster R. CX3CR1+ c-kit+ bone marrow cells give rise to CD103+ and CD103- dendritic cells with distinct functional properties. J Immunol 2008; 181: 6178-6188.
125. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A and Littman DR. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000; 20: 4106-4114.
126. Kikuchi T, Andarini S, Xin H, Gomi K, Tokue Y, Saijo Y, Honjo T, Watanabe A and Nukiwa T. Involvement of fractalkine/CX3CL1 expression by dendritic cells in the enhancement of host immunity against Legionella pneumophila. Infect Immun 2005; 73: 5350-5357.
127. Niess JH, Brand S, Gu X, Landsman L, Jung S, McCormick BA, Vyas JM, Boes M, Ploegh HL, Fox JG, Littman DR and Reinecker HC. CX3CR1- mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005; 307: 254-258.
128. Papadopoulos EJ, Sassetti C, Saeki H, Yamada N, Kawamura T, Fitzhugh DJ, Saraf MA, Schall T, Blauvelt A, Rosen SD and Hwang ST. Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. Eur J Immunol 1999; 29: 2551-2559.